PLN-74809

DRUG6 trials

Sponsors

Pliant Therapeutics, Inc.

Conditions

Acute Respiratory Distress SyndromeIdiopathic Pulmonary FibrosisPrimary Sclerosing CholangitisSARS-CoV-2

Phase 2

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

CompletedNCT04072315

Pliant Therapeutics, Inc.Idiopathic Pulmonary Fibrosis

Start: 2020-02-13End: 2022-07-05Updated: 2023-12-12

Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

CompletedNCT04396756

Pliant Therapeutics, Inc.Idiopathic Pulmonary Fibrosis

Start: 2020-03-03End: 2023-02-15Updated: 2024-06-03

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

CompletedNCT04480840

Pliant Therapeutics, Inc.Primary Sclerosing Cholangitis

Start: 2020-07-27End: 2024-03-18Updated: 2026-01-23

Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19

TerminatedNCT04565249

Pliant Therapeutics, Inc.Acute Respiratory Distress Syndrome, SARS-CoV-2

Start: 2020-10-22End: 2021-08-02Updated: 2022-11-17

Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)

CompletedNCT05621252

Pliant Therapeutics, Inc.Idiopathic Pulmonary Fibrosis

Start: 2022-07-13End: 2024-01-08Updated: 2025-12-05

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

TerminatedNCT06097260

Pliant Therapeutics, Inc.Idiopathic Pulmonary Fibrosis

Start: 2023-11-16End: 2025-04-04Updated: 2026-08-05

Related Papers

Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial.

2026-03-10

Phase II INTEGRIS-PSC trial of bexotegrast, an α<sub>v</sub>β<sub>6</sub>/α<sub>v</sub>β<sub>1</sub> integrin inhibitor, in primary sclerosing cholangitis.

2025-09-261 citations

Dual α <sub>v</sub> β <sub>6</sub> and α <sub>v</sub> β <sub>1</sub> Inhibition over 12 Weeks Reduces Active Type I Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial

American Journal of Respiratory and Critical Care Medicine2025-03-289 citations

Bexotegrast Shows Dose-Dependent Integrin αvβ6 Receptor Occupancy in Lungs of Participants with Idiopathic Pulmonary Fibrosis: A Phase 2, Open-Label Clinical Trial

Annals of the American Thoracic Society2024-11-058 citations

Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial

American Journal of Respiratory and Critical Care Medicine2024-06-0647 citations

INTEGRIS-IPF: A 12-Week, Phase 2a Study Evaluating the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants with Idiopathic Pulmonary Fibrosis

2021-05-011 citations